GRAIL UBS Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Good morning. I'm Doug Schenkel. It's my pleasure to welcome Aaron Freidin, CFO of GRAIL. Aaron, thank you for being here.
Yeah, thanks for having us, Doug.
So, as GRAIL's test, Galleri, moves through FDA review, the key debate is really what approval could unlock from a reimbursement perspective, how important that is to driving broader adoption, and how this positions you and others more broadly in the context of multi-cancer screening. It is a massive opportunity. It could make a huge difference for the general population in the U.S., and of course, you have partnerships that support a potential rollout outside the U.S. more aggressively. So, a really exciting area, a really exciting company, a really interesting time right now. In terms of just providing a roadmap for our discussion, I want to spend a little bit of time on Q3, but I don't want to spend too much time because I think that's kind of missing the point given how we're talking about the long-term opportunities for the company.
I then quickly want to pivot to what's going on with the FDA, where do we go from now, essentially, how do we think about regulatory, building off of that, of course, turning to reimbursement, and even in advance of broad reimbursement, how you can drive broader access. That really is a segue into how you're thinking about commercial adoption and the associated economics. So that's kind of the roadmap. We'll fold in some competitive dynamics as well. So, lots of great things to talk about, but let's start on Q3. Galleri volumes increased, I think it was 24%.
Yeah year over year, but they were down sequentially and came in a little light against what you described as a softer market backdrop.
Again, I do not think we are playing for quarterly volume at this point, but it was light. Why did you come up a little bit light of target, and maybe more importantly, what lessons should we take away from how things are evolving this year?
Yeah, it is a great question, and I agree, this is the short term.
Yep. On the way to longer term.
We are building and playing in this space now, so the long term, of course, is more successful. You are building awareness and so on. So Q3 was, yeah, you said up 24%. I think we are up 36% for the year. Q3 is generally our lowest, from seasonality, our lowest growth quarter. Earlier in the year, we had our NHS-Galleri readout, which of course, we missed the primary endpoint, which was the big headline, even though there was lots of really high-quality clinical utility data in there, stage 4 reduction. We found more stage 1 and 2 cancers in our arm alone compared to all cancers found by screening in the NHS. Do not need to go through it all again. But at that point in time, we are very media sensitive. We have an employer channel.
Employers stopped talking to us, really, and did not start talking to us again until the publications came out and FDA AdCom. Those things caused some slowness in the Q3 period. The self-pay space is very, I would say, volatile. It is hard to figure out really how it is going to grow on a quarter-over-quarter basis. That is because it is very sensitive to media, things like digital health partners and so on, great channel to distribute through, but it is also impacted by how they distribute, how they spend their marketing dollars. They toned down the marketing dollars, we sell less tests. But overall, we are really happy with 24% growth in a slow quarter. With the FDA AdCom positive votes and all the momentum around that, we are now playing with pricing elasticity to try to figure out where our price should really be to drive further expansion prior to reimbursement.
It's interesting. I think every quarter that goes by, at least in advance of FDA approval, in advance of reimbursement, I mean, there is really a consumer behavior dynamic to this right now.
Yeah. Is that fair? Yeah, definitely.
Doesn't sound like, as far as you can tell, there was competitive dynamics that came into play in the quarter.
Yeah, so competition is interesting. We see it adding confusion into the space. Other folks are out there. To be really clear, we all have LDTs right now. We're on the precipice of an FDA approval, cross my fingers. But right now, we're LDTs, but so everybody kind of thinks we're the same. A physician doesn't spend a ton of time looking at the specificity, that sensitivity, and they're making comparisons that you probably shouldn't, caring about case control data versus interventional data. But what we do find is when our PCPs do get in the office, we win once they actually spend the time to invest Once the reps are in there, yeah.
and understand, they win. So we don't lose accounts to competition, but there's 500,000 PCPs out there. So how many people aren't taking a Galleri test because they're being approached and taking one of these others? It's hard to say. Right.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
